London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.  Verdiva looks to challenge the dominance of Novo Nordisk and Eli Lilly, the makers of the two most popular weight loss drugs,  Ozempic and Wegovy.

Topics:  europe s   vc   novo nordisk   eli lilly   ozempic   wegovy   glp-1   july   aiolos this   the next web   verdiva    verdiva   challenge   weight loss drugs   biotech   
BING NEWS:
  • Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
    The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
    01/10/2025 - 3:33 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News